Last reviewed · How we verify
Recombinant Flt3 Ligand
Recombinant Flt3 Ligand stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells by binding to the Flt3 receptor.
Recombinant Flt3 Ligand stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells by binding to the Flt3 receptor. Used for Cancer immunotherapy (in combination with other agents), Hematopoietic stem cell mobilization.
At a glance
| Generic name | Recombinant Flt3 Ligand |
|---|---|
| Also known as | CDX-301, FLT 3 Ligand, FLT3 Ligand, Flt3-Ligand, Flt3L |
| Sponsor | University of Southern California |
| Drug class | Cytokine; Hematopoietic growth factor |
| Target | Flt3 receptor (FLT3) |
| Modality | Biologic |
| Therapeutic area | Oncology; Immunology |
| Phase | Phase 3 |
Mechanism of action
Flt3 Ligand is a cytokine that acts as a growth factor for early hematopoietic cells. By engaging the Flt3 receptor on bone marrow progenitors, it promotes expansion of multiple cell lineages including dendritic cells, which can enhance immune responses. This mobilization of immune cells has been explored therapeutically in cancer immunotherapy and hematopoietic recovery contexts.
Approved indications
- Cancer immunotherapy (in combination with other agents)
- Hematopoietic stem cell mobilization
Common side effects
- Bone pain
- Splenomegaly
- Fever
- Fatigue
Key clinical trials
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (PHASE1)
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (PHASE1)
- FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer (PHASE2)
- Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (PHASE1)
- flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (PHASE2)
- FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (PHASE1, PHASE2)
- Vaccination With Flt3L, Radiation, and Poly-ICLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Flt3 Ligand CI brief — competitive landscape report
- Recombinant Flt3 Ligand updates RSS · CI watch RSS
- University of Southern California portfolio CI